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Relation Between Serum Sodium Concentration and the Hemodynamic
and Clinical Responses to Converting Enzyme Inhibition With
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MILTON PACKER, MD, FACC, NORMA MEDINA, RN, MADELINE YUSHAK, RN
New York. New York
The relation between pretreatment serum sodium con-
centration and the early and late effects of captopril was
examined in 77 consecutive patients with severe chronic
heart failure, in whom cardiac catheterization was per-
formed during initiation of treatment and after 2 to 8
weeks. Two groups of patients were defined: 37 patients
had hyponatremia (serum sodium <135 mEq/liter, group
A) and 40 patients had a normal serum sodium concen-
tration (::::::135 mEq/liter, group B). With first doses of
captopril, patients in group A showed more marked
hemodynamic responses than did patients in group 8
(p < 0.02). The changes in mean arterial pressure and
left ventricular filling pressure seen with first doses of
the drug varied linearly and inversely with the pretreat·
ment serum sodium concentration (r = - 0.58 and r =
- 0.53, respectively); this was likely related to the find-
ing that, before administration of captopril, the serum
sodium concentration varied linearly and inversely with
the logarithm of the plasma renin activity (r = - 0.78).
However, the pretreatment serum sodium concentration
Inhibition of the angiotensin-converting enzyme with cap-
topril is an established approach to the treatment of patients
with severe chronic heart failure (1-4), However, the hemo-
dynamic and clinical responses to short- and long-term ther-
apy with captopril vary, Whereas many patients experience
marked amelioration of dyspnea and fatigue with the drug
(1-5), some individuals show little benefit (6) and others
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did not predict the long-term hemodynamic or clinical
responses to converting enzyme inhibition.
Symptomatic hypotension occurred early in the course
of therapy (within 24 hours of initiating captopril ther-
apy) in 9 (12 %) of the 77 patients; 8 ofthese 9 had severe
hyponatremia (serum sodium <130 mEq/liter) and com-
prised 53% of the 15 patients in our study with such low
serum sodium concentrations. In contrast, symptomatic
hypotension occurring late during therapy (after 1 to 4
weeks) was related to an excessive long-term reduction
in left ventricular filling pressure (:514 mm Hg) and not
to serum sodium concentration.
In conclusion, patients with severe heart failure com-
plicated by severe hyponatremia are more than 30 times
more likely to develop symptomatic hypotension during
initiation of therapy with captopril than are patients with
a serum sodium concentration of 130 mEq/liter or greater.
Patients with severe hyponatremia merit particular cau-
tion during initiation of treatment with converting en-
zyme inhibitors.
demonstrate profound symptomatic hypotension during the
course of treatment ( I ,7,8). Prediction of those patients who
are likely to show beneficial or detrimental effects with
captopril before therapy with the drug is a clinically im-
portant goal.
Determination of plasma renin activity before treatment
has been proposed as a means of selecting patients with
angiotensin-dependent vasoconstriction whose condition is
likely to improve with converting enzyme inhibition (2,9),
However, plasma renin measurements are expensive and
time consuming; furthermore, their value in predicting the
response to acute and chronic captopril therapy has been
questioned (2-4,7,10), A number of investigators (11-13)
have suggested that in patients with severe heart failure,
serum sodium concentration correlates inversely with plasma
renin activity, and that identification of patients with hy-
ponatremia distinguishes a group of individuals with high
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renin heart failure, who may be most likely to benefit from
treatment with captopril (II). However, the usefulness of
serum sodium concentration in predicting the immediate and
long-term hemodynamic and clinical responses to captopril
in patients with severe heart failure has not been directly
investigated.
The present study was designed to examine the relation
between serum sodium concentration and the early and late
effects of captopril in a large group of patients with severe
heart failure, in whom invasive hemodynamic assessment
was performed during short- and long-term treatment with
the drug.
Methods
Study group. The patients in the present study were
chosen from 77 consecutive patients with severe chronic
heart failure who received therapy with captopril during
invasive hemodynamic testing. There were 53 men and 24
women, ranging in age from 29 to 83 years (mean 65). The
cause of heart failure was ischemic cardiomyopathy in 48
patients, primary myocardial disease in 24 patients and per-
sistent severe left ventricular dysfunction associated with
primary valvular heart disease in 5 patients. Normal sinus
rhythm was present in 57 patients, atrial fibrillation in 15
and a ventricular pacemaker rhythm in 5. All patients were
in New York Heart Association functional class IV; how-
ever, all studies were performed during a period of clinical
stability. No patient had had a myocardial infarction within
4 weeks or an episode of acute heart failure within 10 days.
Hemodynamic assessment. Before entry into the study,
all patients were hospitalized for 5 to 7 days, during which
time doses of digoxin and diuretic drugs remained constant
and all vasodilator drugs were discontinued. All patients
were fed a 2 g sodium diet and were permitted free access
to water; patients were entered into the study when body
weight had remained unchanged for at least 4 days. After
the morning doses of digitalis and diuretic drugs were with-
held and after written informed consent was obtained, right
heart catheterization was performed with a triple lumen ftow-
directed catheter for measurement of right atrial, pulmonary
artery and pUlmonary capillary wedge pressures. Arterial
cannulas were inserted into the radial artery of all patients
for measurement of systemic pressures. Measurements were
made with zero reference level at the midaxillary line with
the patient supine. Left ventricular filling pressure was mea-
sured as the mean pulmonary capillary wedge pressure or
as the pulmonary artery diastolic pressure after its identity
with wedge pressure was established. Thermodilution car-
diac output was determined in triplicate by a bedside cardiac
output computer with the use of iced injectate. Heart rate
was derived from a continuously recorded electrocardiogram.
Drug administration. The following hemodynamic
variables were determined repeatedly for at least 2 hours
(with a variation of less than 10%) to ensure the stability
of the baseline hemodynamic state before captopril admin-
istration: mean arterial pressure, heart rate, left ventricular
filling pressure, mean right atrial pressure and cardiac out-
put. If the pulmonary capillary wedge pressure was 15 mm
Hg or greater, each patient received 25 mg of captopril, and
all hemodynamic variables were redetermined every 30 min-
utes for 3 hours. Because the magnitude of the response to
captopril is not dose-dependent (1,2), the second dose of
the drug was determined by each patient's renal function.
This dose was 100 or 150 mg orally in patients with a serum
creatinine level less than 2.2 mg/100 ml, and 25 or 50 mg
orally in patients with a serum level greater than 2.2 mg/100
ml; these doses of captopril were then administered every
8 hours. Thus, the doses of captopril used in this study
ranged from 75 to 450 mg daily (mean dose 258 mg).
The hemodynamic responses to captopril were reeval-
uated 2 to 8 weeks later in 63 patients. Repeat hemodynamic
testing was not performed in 14 patients: 4 died, 3 refused
repeat evaluation, 3 discontinued captopril therapy because
of adverse reactions and 4 had an alteration in their medical
regimen which made the independent evaluation of the re-
sponse to converting enzyme inhibition impossible. In the
remaining 63 patients, doses of digitalis, diuretic drugs and
captopril remained constant throughout the trial (except in
cases of symptomatic hypotension), and dietary intake of
sodium and water was unaltered; compliance with medi-
cations and diet was ensured by close supervision, usually
in a hospitalized setting. After 2 to 8 weeks, the morning
doses of digoxin and diuretic drugs were again withheld,
and right heart catheterization and arterial cannulation were
again performed under conditions identical to those of the
first study. Captopril was then administered in the same
dose as during the preceding 2 to 8 weeks; hemodynamic
determinations were performed every 30 minutes for 3 hours.
Hormonal and clinical determinations. Blood samples
for determination of serum sodium concentration (in all
patients) and for measurement of plasma renin activity by
radioimmunoassay (in 69 of 77 patients) were collected
before the first dose of captopril; serum sodium concentra-
tion (in all patients) and plasma renin activity (in 59 of 63
patients) were redetermined after 2 to 8 weeks of treatment
with captopril, 90 minutes after drug administration. All
samples were drawn at a similar time of day, while the
patient was on a constant 2 g sodium diet and after a min-
imum of 12 hours in the supine position.
Changes in the clinical status of each patient after 2 to
8 weeks' treatment with captopril were assessed in terms
of changes in symptoms of dyspnea and fatigue at rest,
exercise tolerance and body weight. Because all patients
had symptoms at rest or on minimal exertion, formal ex-
ercise testing was not performed.
Data analysis. Mean systemic arterial pressure was de-
termined by electronic filtration. Derived hemodynamic
variables were calculated as follows:
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CI = CO/BSA,
SVR = 80 X (MAP - MRAP)/CO,
where BSA = body surface area; CI = cardiac index Oi-
ters/min per m2); CO = cardiac output; MAP = mean
arterial pressure; MRAP = mean right atrial pressure and
SVR = systemic vascular resistance (dynes.s.cm - ').
During both short- and long-term therapy, the hemody-
namic responses to captopril were assessed at peak drug
effect on left ventricular filling pressure and systemic vas-
cular resistance (0.5 to 2.0 hours after oral administration).
An initial response to captopril was defined as a 5 mm Hg
or greater decrease in left ventricular filling pressure or a
20% or greater decrease in systemic vascular resistance at
peak effect compared with values before captopril
administration.
Patients were classified into two groups on basis of their
serum sodium concentration before captopril therapy: 37
patients (group A) had a serum sodium concentration less
than 135 mEq/liter and 40 patients (group B) had values for
serum sodium 135 mEq/liter or greater; the 15 patients with
a serum sodium concentration less than 130 mEq/liter were
considered to have severe hyponatremia. The hemodynamic
effects of captopril during acute and chronic therapy within
each group were compared by repeated measures two-way
analysis of variance. Control hemodynamic values and the
changes in hemodynamic variables during captopril therapy
between the two groups were compared by the t test for
independent variables. Qualitative differences in the two
groups were analyzed by the chi-square statistic using Yates'
correction for continuity. The hypotheses that a significant
correlation existed between serum sodium concentration and
the hemodynamic and hormonal responses to captopril were
tested by least squares linear regression analysis. Group data
are expressed as mean ± standard error of the mean.
Results
Serum sodium concentration and effects of first doses
of captopril. The control values before the administration
of captopril in groups A and B were similar (Table I).
During the administration of first doses of the drug, patients
in group A with hyponatremia showed a greater increase in
cardiac index and a greater decrease in left ventricular filling
pressure, mean arterial pressure, mean right atrial pressure
and systemic vascular resistance than did patients in group
B who had a normal serum sodium concentration; heart rate
declined similarly in the two groups (Table I). The changes
in mean arterial pressure and left ventricular filling pressure
seen with first doses of captopril varied linearly and in-
versely with the pretreatment serum sodium concentration
(r = -0.58 and r = -0.53, respectively, Fig. IA and
2A).
Twelve of the 77 patients evaluated failed to show any
significant acute response to captopril, and all of them had
a serum sodium concentration of 135 mEq/liter or greater
(12 of 40 group B patients), whereas all 37 group A patients
with hyponatremia responded acutely to the drug (proba-
bility[p] < 0.001, group A versus group B). The two groups
did not differ with respect to age, sex or cause of heart
failure.
Serum sodium concentration and long-term effects of
captopril. In contrast to the relation observed with first
doses of the drug, the long-term changes in cardiac index,
left ventricular filling pressure, mean right atrial pressure
and heart rate in patients in group A (n = 31) and group
B (n = 32) were similar (Table I); this resulted in part
because of the larger variances observed during prolonged
therapy than with initial doses. The hemodynamic responses
in the two groups after 2 to 8 weeks differed only with
respect to changes in mean arterial pressure and systemic
vascular resistance, which were greater in patients with hy-
ponatremia than in patients with a normal serum sodium
concentration. The pretreatment serum sodium concentra-
tion correlated only weakly with long-term changes in mean
arterial pressure (r = - 0.44) and left ventricular filling
pressure (r = -0.33) (Fig. IB and 2B).
Serum sodium concentration and plasma renin activ-
ity. The pretreatment plasma renin activity was signifi-
cantly higher in patients in group A (n = 33) with hypo-
natremia than in patients in group B (n = 36) with a normal
serum sodium concentration (8.6 ± 1.7 versus 1.6 ± 0.2
ng/cc per h, p < 0.00 I). Before the administration of cap-
topril, serum sodium concentration varied linearly and in-
versely with the logarithm of the plasma renin activity
(r = -0.78, P < 0.001) (Fig. 3A).
After 2 to 8 weeks of captopril therapy, serum sodium
concentration increased significantly in patients in group A
(131.4 ± 0.5 to 136.2 ± 0.5 mEq/liter, p < 0.001) but
did not change in patients with normal serum concentrations
before treatment (138.3 ± 0.4 to 138.6 ± 0.7 mEq/liter,
p > 0.20). In contrast, plasma renin activity increased dur-
ing long-term therapy in both groups of patients to a similar
degree (8.0 ± 1.7 to 14.3 ± 1.9 ng/cc per h in group A
In = 301 and 1.6 ± 0.2 to 11.7 ± 2.5 ng/cc per h in group
B [n = 29]). As a result, in contrast to the close relation
seen between serum sodium concentration and plasma renin
activity before captopril, these two variables were not sig-
nificantly correlated after 2 to 8 weeks of treatment with
the drug (r = -0.25) (Fig. 3B).
Weight remained unchanged in group A (66.0 ± 2.8 to
65.8 ± 2.8 kg) but decreased significantly in patients in
group B (64.8 ± 2.1 to 63.2 ± 1.8 kg, p < 0.02).
Serum sodium concentration and symptomatic hy-
potension. Symptomatic hypotension (dizziness or blurred
vision, or both) was observed in 15 (19%) of our 77 patients.
This occurred more frequently in patients in group A (12
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Table 1. Acute and Long-term Hemodynamic Responses to Captopril in Groups A and B
p Value
Group B (group A versus
Group A (serum Na < 135 mEq/liter) (serum Na 2' 135 mEq/liter) group B)
~DI ~LT ~DI ~LT ~DI ~LT
C (n = 37) (n = 31) C (n = 40) (n = 32) A vs. B A vs. B
CI 1.70 + 0.43* +0.19* 1.83 +0.24* + O. I7t <0.02 NS
± 0.07 ± 0.06 ± 0.05 ±om ± 0.05 ± 0.05
MAP 81.5 - 22.2* -17.7* 85.7 - 12.4* -10.2* <0.001 <0.01
± 2.4 ± 1.6 ±1.8 ± 2.4 ±1.I ±1.7
LVFP 27.5 -10.7* - 10.2* 27.1 -6.4* -7.1* <0.001 NS
± 1.0 ± 0.7 ±1.2 ± 0.7 ± 0.6 ±1.I
MRAP 13.3 -4.2* -5.1* 12.1 -3.0* -3.5* <0.02 NS
± 1.I ± 0.4 ± 0.7 ± 1.0 ± 0.3 ± 0.9
HR 84.3 -6.5* -10.5* 82.5 -5.5* -4.8* NS NS
± 2.6 ± 1.4 ± 2.5 ± 2.3 ± 0.8 ± 2.3
SVR 1965 -804* -553* 1961 -416* -323* <0.001 <0.05
± 94 ± 66 ± 82 ± 104 ± 55 ± 61
The short- and long-term effects of captopril in groups A and B are expressed as changes from control ± standard error of the mean. Significance
of the responses within each group compared with control are designated by the symbols, where * = < 0.001 and t = < 0.01. Significance of differences
in the responses between the two groups are shown in the last two columns. Numbers of patients in each group forming the basis of statistical comparisons
are shown beneath each subheading. C = control; CI = cardiac index (liters/min per m2); ~DI = changes seen with the first dose of captopril; ~LT
= changes seen during long-term therapy; HR = heart rate (beats/min); LVFP = left ventricular filling pressure (mm Hg); MAP = mean arterial
pressure (mm Hg); MRAP = mean right atrial pressure (mm Hg); Na = sodium concentration; NS = not significant; p = probability; SVR = systemic
vascular resistance (dynes.s.cm -5).
[32%1of 37 patients) than in those in group B (3 [8%] of
40 patients) (p < 0.001). Ten of the 12 group A patients
with symptomatic hypotension had severe hyponatremia
« 130 mEq/liter).
Hypotensive events occurred at two different times during
our study. Of the 15 patients with hypotensive events, 9
experienced symptoms in the supine position within 24 hours
of initiating treatment with captopril, and 8 of these 9 pa-
tients had severe hyponatremia (125 to 129 mEq/liter). In
contrast, nine patients had hypotensive symptoms late dur-
ing the course of captopril therapy (1 to 4 weeks) and only
during orthostasis. Three of these also had symptomatic
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Figure 1. Relation between pretreat-
ment serum sodium concentration and
the change in mean arterial pressure
with first doses of eaptopril (A) and
during long-term therapy (B). Open
circles in A signify the patients with
symptomatic hypotension within 24
hours of initiating treatment with
captopril.
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Figure 2. Relation between pretreatment serum so-
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hypotension early in the course of therapy; the serum sodium
concentrations before treatment with captopril in these pa-
tients ranged widely (125 to 140 mEq/liter).
The serum sodium concentration was superior to the
pretreatment plasma renin activity and the pretreatment
mean arterial pressure in predicting the occurrence of symp-
tomatic hypotension during the initiation of therapy with
captopril. Of the 9 patients with hypotensive events, 8 had
a serum sodium concentration of less than 130 mEq/liter,
and 53% (8 of 15) of the patients with such severe hypo-
natremia experienced serious hypotension. In contrast, of
the seven patients with early hypotensive symptoms in whom
plasma renin activity was determined before captopril
administration, only four patients had a plasma renin activity
greater than 6 ng/ml per h, and only 29% (4 of 14) of the
patients with such high plasma renin activities developed
symptomatic hypotension. Finally, even though all patients
with hypotensive events had a mean arterial pressure of less
Figure 3. Relation between serum sodium concentra-
tion and plasma renin activity before (A) and during
(B) long-term treatment with captopril. LT-CPT ='
long-term treatment with captopril; Na =' sodium; PRE-
CPT =' before captopril.
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than 80 mm Hg before treatment with captopril, only 25%
(9 of 36 patients) with such low systemic pressures expe-
rienced hypotensive symptoms.
Of the nine patients who experienced symptomatic hy-
potension early during therapy, four did not have recurrent
symptoms when their dose of captopril was reduced to 6.25
or 12.5 mg three times daily, three patients had no recur-
rence despite continued therapy with unchanged doses of
the drug and two patients refused further treatment. In all
cases where the dose of captopril was reduced, it was sub-
sequently possible (after 2 to 7 days) to increase the dose
of the drug to 25 to 100 mg three times daily without a
recurrence of hypotensive symptoms. In the nine patients
with symptomatic hypotension late in the course of treat-
ment, the doses of captopril and diuretic drugs were main-
tained, but dizziness continued. On repeat invasive testing,
the pulmonary capillary wedge pressure in 8 of the 9 patients
was 14 mm Hg or less, (only 3 had had such marked
decreases in intracardiac pressures after first doses of cap-
topril), whereas only 9 of 54 patients who remained asymp-
tomatic had left ventricular filling pressures during long-
term captopril therapy of 14 mm Hg or less (p < 0.001).
After doses of diuretic drugs were reduced by half in patients
with orthostatic symptoms, hypotensive events did not recur.
Serum sodium concentration and clinical responses
to captopril. Within 48 hours of the initiation of captopril
therapy, 11 (30%) of the 36 patients in group A and 3 (8%)
of the 40 patients in group B had dramatic improvement in
their symptoms of dyspnea at rest and orthopnea (p < 0.05,
group A versus B). However, over the next 2 to 8 weeks,
the two groups exhibited similar clinical responses; 19 (61%)
of 31 patients in group A and 20 (63%) of 32 patients in
group B improved by at least one New York Heart Asso-
ciation functional class.
Discussion
Our data indicate that the serum sodium concentration
measured before the institution of captopril therapy in pa-
tients with severe heart failure correlates closely with the
acute effects of the drug but not with the responses seen
during long-term treatment. During initial captopril admin-
istration, patients with hyponatremia demonstrated a more
marked increase in cardiac index and decrease in right and
left ventricular filling pressure, mean arterial pressure and
systemic vascular resistance than did patients with a normal
serum sodium concentration. There was an inverse linear
relation between serum sodium concentration and the im-
mediate hypotensive response to captopril; symptomatic hy-
potension during the initiation of therapy occurred primarily
in patients with severe hyponatremia (serum sodium < 130
mEq/liter). The close relation between hemodynamic re-
sponse and serum sodium concentration did not persist dur-
ing prolonged therapy, however, and thus, long-term clin-
ical responses to captopril were not related to the presence
or magnitude of hyponatremia before treatment.
Hormonal relations in hyponatremic patients with se-
vere heart failure. The reasons underlying the importance
of serum sodium concentration in the acute response to
converting-enzyme inhibition are highly complex. Dzau et
al. (13) have proposed that patients with chronic heart failure
do not form a homogenous patient population but can be
categorized into two groups on the basis of their serum
sodium concentration. Patients with a normal serum sodium
concentration are clinically well compensated and respond
normally to circulatory stress (orthostasis) (13-16). In con-
trast, despite similarly severe degrees of left ventricular
dysfunction, patients with hyponatremia are clinically de-
compensated (13), have elevated levels of stress hormones
(14), commonly show prerenal azotemia (13,17,18) and
have a reduced ability to react to interventions that further
reduce cardiac output (15). In these individuals, the expan-
sion of extracellular volume that accompanies the heart fail-
ure state appears to be insufficient to sustain peripheral
perfusion; instead, systemic pressures are maintained by
activation of neurohumoral forces, particularly the renin-
angiotensin system (19). Both the reduced systemic per-
fusion and the high levels of angiotensin II in these patients
serve to stimulate the release of vasopressin (20,21), whose
levels are markedly elevated in patients with high renin heart
failure (22,23) and whose antidiuretic effects may play an
important role in the pathogenesis of the hyponatremic state
(18,22). Moreover, angiotensin directly stimulates the thirst
center (24,25) and the resulting polydypsia may further lower
the serum sodium concentration. These complex hormonal
interrelations likely explain why we and others noted an
inverse relation between plasma renin activity and serum
sodium concentration (11-13) and why elevated plasma lev-
els of angiotensin II are primarily seen in patients with heart
failure accompanied by hyponatremia (17). Insofar as the
support of systemic pressures in these patients is angioten-
sin-dependent, converting enzyme inhibition with captopril
can be expected to result in immediate and profound hy-
potension (19).
Ofparticular relevance to these hormonal interrelations
is recent evidence (26-28) that the hemodynamic responses
to captopril are not only a consequence of reduced angi-
otensin II formation but also the result of stimulation of
vasodilator prostaglandins. Such enhanced prostaglandin
synthesis results from increased activity of locally active
kinins (29,30), which are degraded by the converting en-
zyme (31) and whose effects are thus potentiated by con-
verting enzyme inhibition (29-31). In this regard, Dzau et
al. (17) recently showed that plasma levels of prostaglandin
E2 are markedly elevated in hyponatremic patients with heart
failure, the degree of elevation being linearly and inversely
related to the serum sodium concentration. These investi-
gators proposed that in patients with hyponatremia, both
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vasodilator (kinins and prostaglandins) and vasoconstrictor
forces (angiotensin and vasopressin) are markedly activated,
probably because systemic hypoperfusion is a common stim-
ulus to both systems (20,32,33). Whereas the increase in
vasoconstrictor hormones serves to support systemic pres-
sures, the increase in prostaglandins serves to preserve re-
gional blood flow in the face of humorally-mediated pe-
ripheral vasoconstriction (33-35) and also to limit the action
of vasopressin on the renal tubular permeability of
water (36,37). Hence, circulatory homeostasis in hypona-
tremic patients appears to be critically dependent on the
maintenance of a delicate balance between constrictor and
dilator mechanisms; this appears not to be the case in pa-
tients with a normal serum sodium concentration (\ 7). The
administration of captopril may thus produce profound hy-
potension in hyponatremic individuals with heart failure,
not only by attenuating formation of vasoconstrictor hor-
mones (angiotensin II) but also by enhancing synthesis of
vasodilator substances (prostaglandin Ee).
Serum sodium concentration as a predictor of symp-
tomatic hypotension. These concepts support our findings
that serum sodium concentration is an excellent predictor
of the occurrence of symptomatic hypotension in patients
with heart failure early in the course of treatment with cap-
topril. Dizziness and blurred vision were observed in nearly
two-thirds of patients with serum sodium concentrations less
than 130 mEq/liter and nearly all of the hypotensive events
occurring within the first 24 hours of therapy were seen in
patients with such severe hyponatremia. These findings have
great clinical importance. Although blood pressure declines
in most patients during initiation of captopril therapy, the
decrease in systemic pressures (although often marked) is
usually well tolerated without symptoms (\-6,38). How-
ever, symptomatic hypotension can occur and (although
transient) is the most feared complication of treatment (1,7,8).
Accordingly, many investigators have suggested that an ex-
tremely cautious approach be followed during initiation of
therapy with captopril; this includes the withdrawal of di-
uretic drugs for several days before treatment (39) and the
use of very small doses of the drug (2.5.6.25 or 12.5 mg)
in an attempt to achieve partial converting enzyme inhibition
(7). Such precautions have been particularly recommended
for those patients felt to be at highest risk of hypotension,
that is, those vigorously treated with intravenous diuretic
drugs (in whom the left ventricular filling pressures before
captopril may be low) and those with a very high plasma
renin activity (8,13,40). However, the usefulness of con-
sidering such patients as high risk subgroups has not been
prospectively evaluated. Hypotension has remained a com-
mon occurrence even in patients on stable doses of diuretics
(1,7,41); furthermore, the risks of right heart catheterization
(for detection of patients with low left heart filling pressures)
and the expense and delays of routine radioimmunoassay
(for determination of plasma renin activity) have diminished
the usefulness of these screening procedures in the selection
of patients at high risk of hypotension.
Our data provide compelling evidence to support the
concept that hyponatremia is an important risk factor for
symptomatic hypotension during initiation of therapy with
captopril. Serum sodium determinations can be performed
rapidly and inexpensively; furthermore, severe hyponatre-
mia predicted the occurrence of symptomatic hypotension
with captopril better than did the plasma renin activity, mean
blood pressure or pulmonary capillary wedge pressure prior
to treatment. Had special precautions for avoiding hypo-
tension been successfully applied to the patients with severe
hyponatremia in our study, the incidence of hypotensive
symptoms during the initiation of captopril therapy would
have declined dramatically (from 12 to I% of treated pa-
tients). However, severe hyponatremia did not predict the
occurrence of late hypotensive reactions with captopril; these
events do not appear to be directly related to the acute
hemodynamic effects of the drug but to an excessive de-
crease in left ventricular filling pressure that may accompany
long-term suppression of plasma aldosterone; this concept
is consistent with the work of Cody et al. (41,42), who
noted that orthostatic hypotension occuring late during the
course of captopril therapy is rapidly corrected by intra-
vascular volume expansion with intravenous saline.
Serum sodium concentration as a predictor of hemo-
dynamic and clinical effects. We found a close relation
between serum sodium concentration and the reduction in
pulmonary capillary wedge pressure with first doses of cap-
topril; this explains why many of our patients with hypo-
natremia improved dramatically within days after institution
of treatment with the drug. Accordingly, we expected (as
have other investigators [11,43]) that patients with hypo-
natremia would be most likely to show hemodynamic benefit
during long-term treatment with captopril. However, we
found little relation between the pretreatment serum sodium
concentration and the long-term hemodynamic or clinical
responses to converting enzyme inhibition; this parallels the
finding that plasma renin activity predicts the acute re-
sponses to captopril more closely than it does the chronic
effects of the drug (2,10). Both observations are consistent
with the concept that a complex relation exists between the
early and late hemodynamic responses to captopril (6). Al-
though the immediate effects of converting enzyme inhi-
bition are frequently sustained (1,3), patients with marked
initial responses may not benefit because these effects be-
come rapidly attenuated (6). Conversely, whereas captopril
is often ineffective in patients who fail to respond to short-
term therapy, some individuals benefit from prolonged treat-
ment despite minimal initial effects (2,6), possibly owing
to a diuretic effect of captopril resulting from the reduction
in plasma aldosterone (5,7,41,42). This is consistent with
our finding that patients with a normal serum sodium con-
centration who showed only modest initial response to the
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drug often had a progressive increase in the magnitude of
hemodynamic benefit during long-term therapy, which was
associated with a significant decrease in weight.
The close inverse relation between serum sodium con-
centration and plasma renin activity observed before therapy
with captopril was no longer present during long-term treat-
ment with the drug. This finding supports the recent ob-
servations of Dzau et al. (44), who noted that serum sodium
concentration provides an excellent index of hormonal status
in untreated patients with heart failure but fails to do so
after converting enzyme inhibition; serum sodium concen-
tration correlates inversely with plasma levels of angiotensin
II and prostaglandin Ez before but not during treatment with
captopril. This finding contrasts with the study of Nicholls
et al. (45), in which the inverse relation between serum
sodium concentration and plasma renin activity was pre-
served during captopril therapy; however, few of their pa-
tients had hyponatremia before treatment. Furthermore, the
electrolyte-hormonal dissociation produced by captopril dif-
fers markedly from the effects of diuretic drugs, which serve
to strengthen the inverse relation between serum sodium
concentration and plasma renin activity in patients with se-
vere heart failure (12,46).
Precautions and limitations. Our findings must be in-
terpreted in the context of certain precautions and limita-
tions. In our study, patients were kept supine during the
acute administration of captopril, and thus, orthostatic changes
early during therapy were not considered. Although we might
expect that orthostasis could provoke hypotensive events in
some patients who might remain asymptomatic while supine
(47), Cody et al. (41,42) showed that orthostatic exacer-
bation of hypotensive changes does not occur during acute
capwpril administration. Also, in our study, patients did
not undergo intensive diuresis before therapy with captopril,
and left ventricular filling pressures before treatment were
greater than 15 mm Hg. Because the administration of vas-
odilator drugs to patients with low filling pressures may
decrease cardiac output (48), such patients would be ex-
pected to be at high risk of hypotensive reactions after con-
verting enzyme inhibition. Accordingly, we would rec-
ommend a cautious approach to the initiation of captopril
in potentially hypovolemic patients, regardless of their serum
sodium concentration.
Lastly, our conclusion that serum sodium concentration
failed to predict long-term benefits during captopril admin-
istration is based on the long-term hemodynamic effects of
the drug at rest and subjective evaluation of symptoms.
Because all of our patients had symptoms at rest or on
minimal exertion, hemodynamic assessment during exercise
was not performed, and clinical improvement was not quan-
tified by changes in exercise duration on a standardized
treadmill test. Hence, our observation that there was little
relation between serum sodium concentration and drug ef-
ficacy cannot be extrapolated to fully ambulatory patients
with heart failure treated with converting-enzyme inhibitors.
However, in a recently completed multicenter double-blind
placebo-controlled trial of captopril therapy in ambulatory
patients with congestive heart failure (49), there was no
significant relation between pretreatment serum sodium con-
centration and the improvement in exercise tolerance after
12 weeks of treatment with the drug (1. Alexander, MD,
personal communication).
Conclusion. In patients with severe chronic failure, the
finding of severe hyponatremia before treatment increased
by more than 30-fold the likelihood of symptomatic hy-
potension occurring during the initiation of therapy with
captopril compared with that in patients with a serum sodium
concentration of 130 mEq/liter or greater. Individuals with
severe hyponatremia merit particular caution during initia-
tion of treatment with converting enzyme inhibitors.
We are greatly indebted to the nurses of the Ames and Rose Cardiac Care
Units of the Mount Sinai Hospital for the excellent care they provided for
our patients during the course of this study.
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